Trials / Completed
CompletedNCT05095168
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- CARE Pharma Shanghai Ltd. · Industry
- Sex
- All
- Age
- 21 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAN106 | CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5. |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2021-02-22
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
- First posted
- 2021-10-27
- Last updated
- 2022-05-25
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05095168. Inclusion in this directory is not an endorsement.